Outcomes of Tacrolimus Therapy in Adults with Refractory Membranous Nephrotic Syndrome: a Prospective, Multicenter Clinical Trial.
Wei Chen,Qinghua Liu,Yunhua Liao,Zhenhua Yang,Jian Chen,Junzhou Fu,Jinli Zhang,Yaozhong Kong,Ping Fu,Tanqi Lou,Zhengrong Liu,Yulian Ji,Zhibin Li,Xueqing Yu
DOI: https://doi.org/10.1097/maj.0b013e31824ce676
IF: 3.462
2013-01-01
The American Journal of the Medical Sciences
Abstract:Introduction: The treatment of adult refractory idiopathic membranous nephropathy with steroid and other immunosuppressant-resistant nephrotic syndrome can be a significant challenge. The authors investigated the efficacy and safety of tacrolimus (TAC) as a promising regimen. Methods: A prospective, multicenter trial was conducted in 9 nephrology centers from 2006 to 2008. Fourteen patients were enrolled. In conjunction with prednisone, TAC was started at 0.05 mg/kg/d, titrated to achieve a trough blood level of 5 to 10 ng/mL for the first 6 months, then reduced to 4 to 6 ng/mL for the subsequent 6 months. The primary endpoints included complete or partial remission. Secondary endpoints included relapse, change of clinical parameters and adverse events. Results: After 12 months, complete remission was achieved in 35.7% of patients and partial remission in 42.9%, yielding a response rate of 78.6%. Proteinuria, serum albumin, cholesterol, triglyceride and low-density lipoprotein were improved significantly (P < 0.001, P < 0.001, P = 0.002, P = 0.01, P = 0.004, respectively). Proteinuria and serum albumin were significantly improved (42.0% +/- 13.2%, P = 0.02; 15.2% +/- 4.5%, P - 0.01, respectively) even after the first month of treatment. One patient relapsed during the subsequent 6 months of follow-up. Adverse events included 2 cases of infection and 1 case each of hyperglycemia, hand tremor, sudden death (nondrug related) and diarrhea. Conclusions: TAC plus prednisone may be an alternative therapeutic option for steroid and general immunosuppressant-resistant membranous nephrotic syndrome patients, with a favorable safety profile. However, given the limitation of a small number of patients in this trial, further study with a larger number and longer follow-up is needed.